INT125978

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.26
First Reported 2005
Last Reported 2009
Negated 0
Speculated 0
Reported most in Abstract
Documents 4
Total Number 4
Disease Relevance 0.88
Pain Relevance 1.37

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transducer activity (Olr833)
Olr833 (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Oxycodone 9 98.24 Very High Very High Very High
tail-flick 4 92.80 High High
Opioid 7 86.64 High High
Potency 1 79.44 Quite High
Disease Link Frequency Relevance Heat
Primary Sclerosing Cholangitis 10 100.00 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833.
Negative_regulation (inhibitor) of PSC833 associated with oxycodone
1) Confidence 0.26 Published 2005 Journal J Pharm Sci Section Title Doc Link 15799017 Disease Relevance 0 Pain Relevance 0.86
The activities of P-gp in these models were characterized using a known substrate (quinidine) and known inhibitors [cyclosporine A (CyA), GF-120918, PSC-833] of P-gp.
Negative_regulation (inhibitors) of PSC-833 associated with primary sclerosing cholangitis
2) Confidence 0.04 Published 2009 Journal J Pharm Sci Section Abstract Doc Link 18855917 Disease Relevance 0.32 Pain Relevance 0.20
Since PSC-833 was found to be a weak inhibitor of CYP 3A4 and to have no inhibitory effects on esterases, phenol sulfotransferases, and glucuronyltransferases, it is suggested PSC-833 enhances intestinal mucosal permeation of these cyclic prodrugs by inhibiting their polarized efflux and not by inhibiting their metabolism.
Negative_regulation (inhibitor) of PSC-833 associated with primary sclerosing cholangitis
3) Confidence 0.01 Published 2009 Journal J Pharm Sci Section Abstract Doc Link 18537150 Disease Relevance 0.29 Pain Relevance 0.15
In contrast, inclusion of PSC-833, a P-gp inhibitor, in the perfusate significantly enhanced (7-16-fold) the permeation of the three cyclic prodrugs.
Negative_regulation (inhibitor) of PSC-833 associated with primary sclerosing cholangitis
4) Confidence 0.01 Published 2009 Journal J Pharm Sci Section Abstract Doc Link 18537150 Disease Relevance 0.27 Pain Relevance 0.16

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox